Islet cell failure in type 2 diabetes
Open accessThe DOI matches its Crossref record; 134 of the 134 references it cites were found in a registry or an index; none of the 272 sources its claims cite is checked for support yet.
Abstract
The major focus of this Review is on the mechanisms of islet beta cell failure in the pathogenesis of obesity-associated type 2 diabetes (T2D). As this demise occurs within the context of beta cell compensation for insulin resistance, consideration is also given to the mechanisms involved in the compensation process, including mechanisms for expansion of beta cell mass and for enhanced beta cell performance. The importance of genetic, intrauterine, and environmental factors in the determination of "susceptible" islets and overall risk for T2D is reviewed. The likely mechanisms of beta cell failure are discussed within the two broad categories: those with initiation and those with progression roles.
Overview
CoChat Summary
## TL;DR
This is a 2006 review arguing that type 2 diabetes develops when insulin-resistant islets can no longer sustain compensatory b cell function, leading first to dysfunction and then progressive loss of b cell mass. It emphasizes that “susceptible” islets are shaped by genetic, intrauterine, and environmental factors, and that hyperglycemia accelerates damage through glucotoxic and glucolipotoxic mechanisms.
## Key findings
- In longitudinal studies, insulin levels rise during the normoglycemic and prediabetes phases and then decline when fasting glycemia exceeds the upper normal limit of 5.5 mM, marking b cell failure.
- A longitudinal study in Pima Indians found that b cell dysfunction was the major determinant of progression from normoglycemia to diabetes.
- In autopsy pancreata from 124 subjects, the paper reports a 40% and 63% loss of islet b cell volume in obese subjects with impaired fasting glucose and T2D, respectively, compared with weight-matched controls; lean T2D subjects had a 41% loss versus lean controls.
- The paper reports that the STOP-NIDDM trial showed acarbose treatment of IGT subjects reduced the risk of progression to diabetes by 36%.
## Methods
- Narrative review of mechanistic, animal, human postmortem, genetic, and epidemiologic studies on islet b cell compensation and failure in obesity-associated T2D.
- Synthesizes findings from rodent models (including ZF, ZDF, DBA2, GK, and IUGR models) and human islet/pancreas studies, including a transcript profiling study of 7 normal and 5 T2D human islet samples.
- Main analysis is integrative and conceptual: it organizes evidence into mechanisms that promote compensation and mechanisms with initiation versus progression roles in b cell failure.
## Limitations
- The paper states that the mechanisms of b cell compensation are “not fully understood,” and that the role of several proposed factors remains to be established or warrants further investigation.
- It explicitly notes uncertainty about several mechanisms, including whether nonimmune islet inflammation contributes in vivo, whether IAPP is causal in b cell dysfunction and demise, and whether reduced ARNT expression is an early defect or a consequence.
- Evident from the text: this is a review, not a new experimental study, so its conclusions depend on the quality and consistency of the cited animal and human studies rather than on a single primary dataset.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
0 Valid · 1 Not valid · 164 Not checked · 38 Own results and interpretations
In the paper
“Longitudinal studies of subjects that develop T2D show a rise in insulin levels in the normoglycemic and prediabetes phases that keep glycemia near normal despite the insulin resistance ( b cell compensation), followed by a decline when fasting glycemia surpasses the upper limit of normal of 5.5 mM ( b cell failure) (5) (Figure 1).”
What the sources say
- Not checked yetcites [5]
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“With respect to the latter, increases were observed in enzymes and metabolites involved in anaplerosis and the malate-pyruvate and citratepyruvate shuttles of ZF islets (12).”
What the sources say
- Not checked yetcites [12]
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“Inhibition of these pathways by phenylacetic acid, which inhibits PC, markedly impeded GSIS (12).”
What the sources say
- Not checked yetcites [12]
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
None of the sources cited for this claim have been checked yet.
In the paper
“Studies of islet b cell compensation within models that maintain normoglycemia show upregulation of glucose metabolism pathways (12, 13, 31).”
What the sources say
- Not checked yetcites [12]
- Not checked yetcites [13]
- Not checked yetcites [31]
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“A recent study in Zucker fatty (ZF) rats has provided strong support for PKB activation in the b cell growth response to insulin resistance in this normoglycemic model (11).”
What the sources say
- Not checked yetcites [11]
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
116 more claims
Create a free account to see all 203 claims and to verify the 272 references still open.
- It may state two separate claims as one. 71
- Probably not a substantial claim. 13
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Importantly, several of these studies have demonstrated that fatty acids do not induce beta-cell dysfunction in the absence of elevated glucose, highlighting that fatty acids and glucose are not cytotoxic independently.168,169”
From A review of current trends with type 2 diabetes epidemiology, aetiology, pathogenesis, treatments and future perspectives (2021) · cites this paper as [169]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Notably, impairment of insulin secretion in the presence of an intact β-cell mass also occurs in the early stages of human age-related diabetes123.”
From The telomere syndromes (2012) · cites this paper as [123]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Minor deficiencies in the β-cell machinery may only be exposed in times of metabolic stress, such as pregnancy [75].”
From The Pathophysiology of Gestational Diabetes Mellitus (2018) · cites this paper as [75]
Experimental — accuracy not yet measured
Citations
Cites
Mootha, V. K., Lindgren, C. M., Eriksson, K.-F., Subramanian, A., Sihag, S., Lehar, J., Puigserver, P., Carlsson, E., Ridderstråle, M., Laurila, E., et al. (2003) · Nature Genetics · doi:10.1038/ng1180 · Cited by 10,197
Global and societal implications of the diabetes epidemic
Zimmet, P., Alberti, K. G. M. M., & Shaw, J. (2001) · Nature · doi:10.1038/414782a · Cited by 5,883
β-Cell Deficit and Increased β-Cell Apoptosis in Humans With Type 2 Diabetes
Butler, A. E., Janson, J., Bonner-Weir, S., Ritzel, R., Rizza, R. A., & Butler, P. C. (2003) · Diabetes · doi:10.2337/diabetes.52.1.102 · Cited by 4,011
Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial
Chiasson, J.-L., Josse, R. G., Gomis, R., Hanefeld, M., Karasik, A., & Laakso, M. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08905-5 · Cited by 2,543
Barker, D. J. P., Hales, C. N., Fall, C. H. D., Osmond, C., Phipps, K., & Clark, P. M. S. (1993) · Diabetologia · doi:10.1007/bf00399095 · Cited by 2,468
Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes
Grant, S. F. A., Thorleifsson, G., Reynisdottir, I., Benediktsson, R., Manolescu, A., Sainz, J., Helgason, A., Stefansson, H., Emilsson, V., Helgadottir, A., et al. (2006) · Nature Genetics · doi:10.1038/ng1732 · Cited by 2,287
The biology of incretin hormones
Drucker, D. J. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.004 · Cited by 2,210
Mitochondrial dysfunction and type 2 diabetes
Lowell, B. B., & Shulman, G. I. (2005) · Science · doi:10.1126/science.1104343 · Cited by 2,070
Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase
Minokoshi, Y., Kim, Y.-B., Peroni, O. D., Fryer, L. G. D., Müller, C., Carling, D., & Kahn, B. B. (2002) · Nature · doi:10.1038/415339a · Cited by 2,053
Weyer, C., Bogardus, C., Mott, D. M., & Pratley, R. E. (1999) · Journal of Clinical Investigation · doi:10.1172/jci7231 · Cited by 1,940
Cited by
Items 701–800 of 1,002
Wang, Z., Ni, X., Zhang, L., Sun, L., Zhu, X., Zhou, Q., Yang, Z., & Yuan, H. (2020) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s279104 · Cited by 37
Pancreatic Islets Accumulate Cadmium in a Rodent Model of Cadmium-Induced Hyperglycemia
Fitzgerald, R., Olsen, A., Nguyen, J., Wong, W. P. S., Muayed, M. E., & Edwards, J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms22010360 · Cited by 32
“While the nephrotoxic effects of Cd are well known reports show significant correlations between exposure to Cd and the prevalence of prediabetes and/or type II diabetes mellitus (T2DM) in countries such as Pakistan [7,8], China [9], USA [10,11], and Australia [12].”
BackgroundInfluentialABO Genotype, ‘Blood-Type’ Diet and Cardiometabolic Risk Factors
Wang, J., García‐Bailo, B., Nielsen, D. E., & El‐Sohemy, A. (2014) · PLoS ONE · doi:10.1371/journal.pone.0084749 · Cited by 42
“[39,40].”
Novelli, M., Bonamassa, B., Masini, M., Funel, N., Canistro, D., Tata, V. D., Martano, M., Soleti, A., Campani, D., Paolini, M., et al. (2010) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-010-0524-7 · Cited by 34
Deoxyhypusine synthase haploinsufficiency attenuates acute cytokine signaling
Templin, A. T., Maier, B., Nishiki, Y., Tersey, S. A., & Mirmira, R. G. (2011) · Cell Cycle · doi:10.4161/cc.10.7.15206 · Cited by 35
Abaraviciene, S. M., Lundquist, I., Galvanovskis, J., Flodgren, E., Olde, B., & Salehi, A. A. (2008) · PLoS ONE · doi:10.1371/journal.pone.0002182 · Cited by 37
Ho, B. X., Teo, A. K. K., & Ng, N. H. J. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1375177 · Cited by 41
“A vicious cycle exists in which persistent hyperglycemia leads to progressive decline in b cell compensation and eventual onset of b cell dysfunction (7 – 9).”
BackgroundThe pancreatic beta cell surface proteome
Stützer, I., Esterházy, D., & Stoffel, M. (2012) · Diabetologia · doi:10.1007/s00125-012-2531-3 · Cited by 37
Sun, M. Y., Yoo, E., Green, B. J., Altamentova, S. M., Kilkenny, D. M., & Rocheleau, J. V. (2012) · Biophysical Journal · doi:10.1016/j.bpj.2012.10.028 · Cited by 34
Cheng, S. T. W., Li, S. Y. T., & Leung, P. S. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20102517 · Cited by 32
miR-494 protects pancreatic β-cell function by targeting PTEN in gestational diabetes mellitus
He, Y., Bai, J., Liu, P., Dong, J., Tang, Y., Zhou, J., Han, P., Xing, J. Q., Chen, Y., & Yu, X. (2017) · EXCLI journal · doi:10.17179/excli2017-491 · Cited by 31
“Decline in β-cell function is characterized by a reduction of β-cell mass caused by an increased apoptosis rate and defective insulin production and secretion from the remaining β-cells (Weir et al., 2001; Butler et al., 2003; Maedler and Donath, 2004; Prentki and Nolan, 2006).”
BackgroundFlavonoids Identification and Pancreatic Beta-Cell Protective Effect of Lotus Seedpod
Lee, M., Chyau, C.-C., Wang, C.-P., Wang, T., Chen, J., & Lin, H. (2020) · Antioxidants · doi:10.3390/antiox9080658 · Cited by 37
“In hyperglycemia condition, insulin resistance, cell inflammation, and excess of lipids and other metabolic fuels, containing fatty acid and glucose, trigger beta-cell dysfunction over time [1,3].”
Wei, Q., Sun, Y., & Zhang, J. (2012) · Peptides · doi:10.1016/j.peptides.2012.06.018 · Cited by 33
Involvement of Oxidative Stress in Suppression of Insulin Biosynthesis under Diabetic Conditions
Kaneto, H., & Matsuoka, T. (2012) · International Journal of Molecular Sciences · doi:10.3390/ijms131013680 · Cited by 39
Analysis of gene expression in pancreatic islets from diet-induced obese mice
Imai, Y., Patel, H. R., Doliba, N. M., Matschinsky, F. M., Tobias, J. W., & Ahima, R. S. (2008) · Physiological Genomics · doi:10.1152/physiolgenomics.00050.2008 · Cited by 31
Mortality in Individuals Treated With Glucose-Lowering Agents: A Large, Controlled Cohort Study
Claesen, M., Gillard, P., Smet, F. D., Callens, M., Moor, B. D., & Mathieu, C. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-3184 · Cited by 32
“Glucose lowering therapy in type 2 diabetes is challenging, due to the progressive nature of the disease by the underlying failure of the insulin-secreting -cells (1).”
BackgroundMagnolol protects pancreatic β-cells against methylglyoxal-induced cellular dysfunction
Suh, K. S., Chon, S., Jung, W., & Choi, E. M. (2017) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2017.09.014 · Cited by 30
Pleiotropic effects of hypoglycemic agents: implications in asthma and COPD
Rogliani, P., Ora, J., Daniele, N. D., & Lauro, D. (2018) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2018.01.002 · Cited by 32
Rawat, A. K., Misra, G., Saxena, M., Tripathi, S., Dubey, D., Saxena, S., Aggarwal, A., Gupta, V., Khan, M., & Prakash, A. (2018) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2018.09.009 · Cited by 30
Sjöblad, S. (2019) · Medical Hypotheses · doi:10.1016/j.mehy.2019.02.027 · Cited by 34
Chu, K. Y., Mellet, N. A., Thai, L. M., Meikle, P. J., & Biden, T. J. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101023 · Cited by 32
Skovsø, S., Damgaard, J., Fels, J. J., Olsen, G. S., Wolf, X. A., Rolin, B., & Holst, J. J. (2015) · International Journal of Obesity · doi:10.1038/ijo.2015.92 · Cited by 32
Insulin resistance in chronic hepatitis C
Bernsmeier, C., & Heim, M. H. (2009) · Swiss Medical Weekly · doi:10.4414/smw.2009.12765 · Cited by 36
Lastra, G., & Manrique, C. M. (2007) · Antioxidants and Redox Signaling · doi:10.1089/ars.2007.1615 · Cited by 34
Resveratrol may be beneficial in treatment of diabetic foot syndrome
Bashmakov, Y. K., Assaad-Khalil, S. H., & Petyaev, I. M. (2011) · Medical Hypotheses · doi:10.1016/j.mehy.2011.05.016 · Cited by 29
Multi-layered computational gene networks by engineered tristate logics
Shao, J., Qiu, X., Zhang, L., Li, S., Xue, S., Si, Y., Li, Y., Jiang, J., Wu, Y., Xiong, Q., et al. (2024) · Cell · doi:10.1016/j.cell.2024.07.001 · Cited by 35
“54 From a biocomputational perspective, such treatment regimen could be epitomized with a (over)simplified Boolean truth table (Figure 6A); whereas T2D patients can be generally treated by administration of one single drug (e.g., VA; input 1) triggering secretion of both INS and GLP-1, INS-resistant…”
Zhou, Y., Sun, P. G., Wang, T., Chen, K., Zhu, W., & Wang, H. (2015) · PLoS ONE · doi:10.1371/journal.pone.0132411 · Cited by 32
“During the development of type 2 diabetes (T2D), obesity induced elevation level of free fatty acids (FFAs) causes both insulin resistance and pancreatic β-cell failure [1, 2].”
BackgroundMicroRNAs and the functional β cell mass: For better or worse
Guay, C., & Regazzi, R. (2015) · Diabetes & Metabolism · doi:10.1016/j.diabet.2015.03.006 · Cited by 30
Characterization of β‐Cell Mass and Insulin Resistance in Diet‐induced Obese and Diet‐resistant Rats
Paulsen, S. J., Jelsing, J., Madsen, A. N., Hansen, G., Lykkegaard, K., Larsen, L. K., Larsen, P. J., Levin, B. E., & Vrang, N. (2009) · Obesity · doi:10.1038/oby.2009.245 · Cited by 32
Exendin-4 stimulates islet cell replication via the IGF1 receptor activation of mTORC1/S6K1
Xie, J., El-Sayed, N. M., Cheng, Q., Zhao, X., Moore, C. E., & Herbert, T. P. (2014) · Journal of Molecular Endocrinology · doi:10.1530/jme-13-0200 · Cited by 32
“Type 2 diabetes mellitus (T2DM) is a disorder that is characterized by high blood glucose in the context of insulin resistance and relative insulin deficiency (Lingohr et al. 2002, Prentki & Nolan 2006).”
BackgroundLin, H., Yin, Y., Zhang, J. X., Xuan, H., Zheng, Y., Zhan, S., Zhu, Y., & Han, X. (2012) · Diabetologia · doi:10.1007/s00125-012-2643-9 · Cited by 28
Purwana, I., Liu, J. J., Portha, B., & Buteau, J. (2017) · Diabetologia · doi:10.1007/s00125-017-4310-7 · Cited by 34
“Results Glucolipotoxicity inhibits HSF1 activity via CBP-mediated acetylationWe first sought to explore the regulation of HSF1 in pancreatic beta cells in response to glucolipotoxicity, a condition of metabolic stress that provokes ER stress [19–21]) and is thought to mimic the hyperglycaemic and hyperlipidaemic envir…”
BackgroundVincamine as a GPR40 agonist improves glucose homeostasis in type 2 diabetic mice
Du, T., Yang, L., Xu, X., Shi, X., Xu, X., Lu, J., Lv, J., Huang, X., Chen, J., Wang, H., et al. (2018) · Journal of Endocrinology · doi:10.1530/joe-18-0432 · Cited by 32
Mishra, A., Liu, S., Promes, J. A., Harata, M., Sivitz, W. I., Fink, B. D., Bhardwaj, G., O'Neill, B. T., Chen, K., Sah, R., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.144341 · Cited by 28
“Aichler et al reported the accumulation of stearoyl-carnitine (C18:0) in islets affected by T2D and in mouse models of T2D (30).”
BackgroundInfluentialRamin-Mangata, S., Thedrez, A., Nativel, B., Diotel, N., Blanchard, V., Wargny, M., Aguesse, A., Billon-Crossouard, S., Vindis, C., Le May, C., et al. (2021) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2021.03.044 · Cited by 28
Plasma triacylglycerols are biomarkers of β-cell function in mice and humans
Sánchez-Archidona, A. R., Cruciani‐Guglielmacci, C., Roujeau, C., Wigger, L., Lallement, J., Denom, J., Barovic, M., Kassis, N., Mehl, F., Weitz, J., et al. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101355 · Cited by 41
“Type 2 diabetes (T2D) is a chronic hyperglycemic condition characterized by reduced glucose-stimulated insulin secretion (GSIS) and increased insulin resistance of insulin target tissues [1,2].”
BackgroundGeranylgeranyl diphosphate synthase: Role in human health, disease and potential therapeutic target
Muehlebach, M. E., & Holstein, S. A. (2023) · Clinical and Translational Medicine · doi:10.1002/ctm2.1167 · Cited by 32
Raj, R., Bhatti, J. S., Badada, S. K., & Ramteke, P. W. (2015) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2630 · Cited by 31
Gallwitz, B., & Häring, H. (2009) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01095.x · Cited by 30
Ko, G. T. C., So, W. Y., Tong, P. C. Y., Chan, J. C. N., Yang, X., Ma, R. C., Kong, A. P. S., Ozaki, R., Yeung, C. Y., Chow, C. C., et al. (2009) · Canadian Medical Association Journal · doi:10.1503/cmaj.081545 · Cited by 29
Luo, G.-C., Kong, X., Lü, L., Xu, X., Wang, H., & Ma, X. (2012) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2012.11.016 · Cited by 33
The In Vivo β-to-β-Cell Chat Room: Connexin Connections Matter
Meda, P. (2012) · Diabetes · doi:10.2337/db12-0336 · Cited by 28
Bissonnette, S., Saint-Pierre, N., Lamantia, V., Cyr, Y., Wassef, H., & Faraj, M. (2015) · Nutrition and Diabetes · doi:10.1038/nutd.2015.30 · Cited by 35
Han, Y., Jung, H. W., & Park, Y. (2012) · BMC Complementary and Alternative Medicine · doi:10.1186/1472-6882-12-154 · Cited by 28
Mitochondrial Hormesis in PancreaticβCells: Does Uncoupling Protein 2 Play a Role?
Li, N., Stojanovski, S., & Maechler, P. (2012) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2012/740849 · Cited by 31
Backe, M. B., Andersson, J., Bacos, K., Christensen, D. P., Hansen, J. B., Dorosz, J., Gajhede, M., Dahlby, T., Bysani, M., Kristensen, L. H., et al. (2017) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2017.07.001 · Cited by 34
“…expression ultimately leading to β-cell 48 dysfunction and death (Willcox, Richardson, Bone et al., 2009,Prokopenko, McCarthy and Lindgren, 49 2008,Prentki and Nolan, 2006), and histone PTMs, e.g. by acetylation or methylation, are altered by the 50 diabetic milieu, e.g. inflammatory cytokines…”
BackgroundMethodParaneoplastic β Cell Dedifferentiation in Nondiabetic Patients with Pancreatic Cancer
Wang, Y., Ni, Q., Sun, J., Xu, M., Xie, J., Zhang, J., Fang, Y., Ning, G., & Wang, Q. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz224 · Cited by 33
Suthamwong, P., Minami, M., Okada, T., Shiwaku, N., Uesugi, M., Yokode, M., & Kamei, K. (2020) · BMC Complementary Medicine and Therapies · doi:10.1186/s12906-020-02933-4 · Cited by 28
Dhumad, M. M., Hamdan, F. B., Khudhair, M. S., & Al‐Matubsi, H. Y. (2021) · Scientific Reports · doi:10.1038/s41598-021-80962-w · Cited by 38
Kaur, S., Mirza, A. H., Overgaard, A. J., Pociot, F., & Størling, J. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.630109 · Cited by 28
“…by prolonged metabolic stress exerted by e.g., free fatty acids (FFA) such as palmitate, and by the persistent increased demand for insulin production due to peripheral insulin resistance ultimately leading to β-cell failure (Prentki and Nolan, 2006; Oh et al., 2018; Wysham and Shubrook, 2020).”
BackgroundPoleboina, S., Sheth, V. G., Sharma, N., Sihota, P., Kumar, N., & Tikoo, K. (2022) · Nanomedicine · doi:10.2217/nnm-2021-0401 · Cited by 32
Winn, N. C., Cottam, M. A., Bhanot, M., Caslin, H. L., Garcia, J. N., Drigo, R. A. E., & Hasty, A. H. (2022) · Diabetes · doi:10.2337/db22-0161 · Cited by 31
Do thrifty genes exist? Revisiting uricase
Johnson, R. J., Sánchez‐Lozada, L. G., Nakagawa, T., Rodríguez‐Iturbe, B., Tolan, D. R., Gaucher, E. A., Andrews, P., & Lanaspa, M. A. (2022) · Obesity · doi:10.1002/oby.23540 · Cited by 32
“explain why lowering fructose intake is so beneficial in children with metabolic syndrome [105] and why obesity and diabetes are harder to reverse in the adult who has had these conditions for a long time [76, 106, 107].”
BackgroundTharaheswari, M., Nakkala, J. R., Jeepipalli, S. P. K., Raja, K., Chandra, V. K., Mohan, V. K., & Sadras, S. R. (2014) · European Food Research and Technology · doi:10.1007/s00217-014-2322-9 · Cited by 31
A molecular rheostat at the interface of cancer and diabetes
Osman, M. A., Sarkar, F. H., & Rodriguez-Boulan, E. J. (2013) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2013.04.005 · Cited by 31
“While insulin resistance can be reversible therapeutically, the loss of functional β-cell mass cannot at present be reversed, which has led to the concept that loss of β-cell mass is a major driver of T2D [12-17].”
BackgroundResultOmikorede, O., Cheng, Q., Gorman, T., Chapman, P. J., Yu, A., Smith, D. M., & Herbert, T. P. (2013) · Nutrition and Diabetes · doi:10.1038/nutd.2013.35 · Cited by 30
Scomparin, D. X., Grassiolli, S., Gomes, R. M., Torrezan, R., de Oliveira, J. C., Gravena, C., Pêra, C. C., & Mathias, P. C. D. F. (2011) · Endocrine Research · doi:10.3109/07435800.2010.534750 · Cited by 28
IL-13 improves beta-cell survival and protects against IL-1beta-induced beta-cell death
Rütti, S., Howald, C., Arous, C., Dermitzakis, E. T., Halban, P. A., & Bouzakri, K. (2015) · Molecular Metabolism · doi:10.1016/j.molmet.2015.11.003 · Cited by 29
Cochran, B. J., Hou, L., Manavalan, A. P. C., Moore, B. M., Tabet, F., Sultana, A., Torres, L. C., Tang, S., Shrestha, S., Senanayake, P., et al. (2016) · Diabetes · doi:10.2337/db16-0668 · Cited by 30
Eraky, S. M., Abdel‐Rahman, N., & Eissa, L. A. (2017) · Prostaglandins Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2017.06.009 · Cited by 30
Interorgan Crosstalk Contributing toβ-Cell Dysfunction
Tanabe, K., Amo-Shiinoki, K., Hatanaka, M., & Tanizawa, Y. (2017) · Journal of Diabetes Research · doi:10.1155/2017/3605178 · Cited by 33
The role of membrane excitability in pancreatic β-cell glucotoxicity
Shyr, Z. A., Wang, Z., York, N., Nichols, C. G., & Remedi, M. S. (2019) · Scientific Reports · doi:10.1038/s41598-019-43452-8 · Cited by 31
The Lysine Demethylase KDM5B Regulates Islet Function and Glucose Homeostasis
Backe, M. B., Jin, C., Andreone, L., Sankar, A., Agger, K., Helin, K., Madsen, A. N., Poulsen, S. S., Bysani, M., Bacos, K., et al. (2019) · Journal of Diabetes Research · doi:10.1155/2019/5451038 · Cited by 28
Kaneto, H., Matsuoka, T., Kimura, T., Obata, A., Shimoda, M., Kamei, S., Mune, T., & Kaku, K. (2015) · Journal of Diabetes · doi:10.1111/1753-0407.12331 · Cited by 31
Pépin, É., Al‐Mass, A., Attané, C., Zhang, K., Lamontagne, J., Lussier, R., Madiraju, S. R. M., Joly, E. C., Ruderman, N. B., SLADEK, R. M., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0153017 · Cited by 30
Self-citationFive stages of progressive β-cell dysfunction in the laboratory Nile rat model of type 2 diabetes
Yang, K., Gotzmann, J., Kuny, S., Huang, H. M., Sauvé, Y., & Chan, C. B. (2016) · Journal of Endocrinology · doi:10.1530/joe-15-0517 · Cited by 30
“2004, Prentki & Nolan 2006).”
Wang, T., Ma, X., Tang, T., Jin, L., Peng, D., Zhang, R., Chen, M., Yan, J. Y., Wang, S., Yan, D., et al. (2016) · International Journal of Obesity · doi:10.1038/ijo.2016.155 · Cited by 26
Ahangarpour, A., Zeidooni, L., Rezaei, M., Alboghobeish, S., Samimi, A., & Oroojan, A. A. (2017) · PubMed Central · doi:10.22038/ijbms.2017.9567 · Cited by 29
Murtishaw, A. S., Heaney, C. F., Bolton, M. M., Belmonte, K. C. D., Langhardt, M. A., & Kinney, J. W. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.04.021 · Cited by 28
“As insulin resistance persists during Type-2 DM, pancreatic b-cells continually upregulate the production of insulin to clear the buildup of glucose in the bloodstream, ultimately leading to progressive b-cell failure (Prentki and Nolan, 2006).”
Good, A. L., & Stoffers, D. A. (2020) · Diabetes · doi:10.2337/dbi18-0068 · Cited by 28
Nichols, C. G., York, N., & Remedi, M. S. (2022) · Diabetes · doi:10.2337/db21-0755 · Cited by 34
Cholesterol‐enriched membrane rafts and insulin secretion
Dirkx, R. A., & Solimena, M. (2012) · Journal of Diabetes Investigation · doi:10.1111/j.2040-1124.2012.00200.x · Cited by 32
Mu, P., Chen, Y., Lu, H., Wen, X., Zhang, Y., Xie, R., Shu, J., Wang, M., & Zeng, L. (2012) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.1292 · Cited by 30
Bi, Y., Tong, G. Y., Yang, H., Cai, M., Ma, J. H., Liang, J., Xin, B., Miao, H., Peng, Z., & Zhu, D. (2013) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2443 · Cited by 28
de Oliveira, R. B., Carvalho, C. P. D. F., Polo, C. C., Dorighello, G. G., Boschero, A. C., Oliveira, H. C. F., & Collares‐Buzato, C. B. (2014) · International Journal of Experimental Pathology · doi:10.1111/iep.12084 · Cited by 28
“These metabolic disturbances characterize the well-known predia- betic state that corresponds to the initial phase of the T2DM (Rhodes 2005; Ding et al. 2010; Tripathy & Chavez 2010).”
BackgroundInfluentialGao, F., Fang, Q., Zhang, R., Lu, J., Lu, H., Wang, C., Ma, X., Xu, J., Jia, W., & Xiang, K. (2009) · Endocrine Journal · doi:10.1507/endocrj.k08e-322 · Cited by 28
Kang, K. C., Shin, S. H., Lee, Y. J., & Heo, Y. S. (2012) · Journal of the Korean Surgical Society · doi:10.4174/jkss.2012.82.6.347 · Cited by 29
Wang, W., Liu, Y., Chen, Y., Cao, C.-P., Xiang, Y., Zhang, D., Han, L., Zhao, H., & Liu, G. (2009) · Peptides · doi:10.1016/j.peptides.2009.11.011 · Cited by 28
Intercellular Communication in the Islet of Langerhans in Health and Disease
Ng, X. W., Chung, Y. H., & Piston, D. W. (2021) · Comprehensive physiology · doi:10.1002/cphy.c200026 · Cited by 43
Biomarkers of insulin sensitivity/resistance
Kosmas, C. E., Sourlas, A., Oikonomakis, K., Zoumi, E.-A., Papadimitriou, A., & Kostara, C. E. (2024) · Journal of International Medical Research · doi:10.1177/03000605241285550 · Cited by 38
“24,25 Hyperinsulinemia may also exacerbate IR, often leading to a vicious cycle of IR and hyperinsulinemia, wherein both are results and drivers, which eventually culminates in b -cell failure.”
BackgroundDapagliflozin: a review on efficacy, clinical effectiveness and safety
Paisley, A. N., Yadav, R., Younis, N., Rao‐Balakrishna, P., & Soran, H. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2013.740009 · Cited by 28
Li, Q., Li, B., Miao, X., Ramgattie, C., Gao, Z., & Liu, J. (2016) · Endocrinology · doi:10.1210/en.2016-1551 · Cited by 26
Šišoláková, I., Hovancová, J., Oriňáková, R., Oriňák, A., Trnková, L., Třísková, I., Farka, Z., Pastucha, M., & Radoňak, J. (2020) · Journal of Electroanalytical Chemistry · doi:10.1016/j.jelechem.2020.113881 · Cited by 27
Klf6 protects β-cells against insulin resistance-induced dedifferentiation
Dumayne, C., Tarussio, D., Sánchez-Archidona, A. R., Picard, A., Basco, D., Berney, X. P., Ibberson, M. R., & Thorens, B. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2020.02.001 · Cited by 28
White sweet potato ameliorates hyperglycemia and regenerates pancreatic islets in diabetic mice
Shih, C., Chen, C., Varga, V., Shih, L.-C., Chen, P.-R., Lo, S.-F., Shyur, L., & Li, S. (2020) · Food & Nutrition Research · doi:10.29219/fnr.v64.3609 · Cited by 28
Is GDF-15 level associated with gestational diabetes mellitus and adverse perinatal outcomes?
Yakut, K., Öcal, F. D., Öztürk, F. H., Öztürk, M., Oğuz, Y., Sınacı, S., & Çağlar, T. (2021) · Taiwanese Journal of Obstetrics and Gynecology · doi:10.1016/j.tjog.2020.12.004 · Cited by 29
New Aspects of Diabetes Research and Therapeutic Development
Satin, L. S., Soleimanpour, S. A., & Walker, E. M. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000160 · Cited by 34
MicroRNAs in type 2 diabetes mellitus: potential role of physical exercise
Caria, A. C. I., Sousa, R. A. L. D., Roever, L., Fernandes, T. M., de Oliveira, E. M., Aras, R., & Souza, B. S. D. F. (2022) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2301029 · Cited by 27
3-Substituted 3-(4-aryloxyaryl)-propanoic acids as GPR40 agonists
Walsh, S. P., Severino, A., Zhou, C., He, J., Liang, G., Tan, C. P., Cao, J., Eiermann, G. J., Xu, L., Salituro, G., et al. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2011.03.114 · Cited by 28
Mezghenna, K., Pomiès, P., Chalançon, A., Castex, F., Leroy, J., Niclauß, N., Nadal, B., Cambier, L., Cazevieille, C., Petit, P., et al. (2011) · Diabetologia · doi:10.1007/s00125-011-2264-8 · Cited by 28
Joly, E. C., Roduit, R., Peyot, M., Habinowski, S. A., Ruderman, N. B., Witters, L. A., & Prentki, M. (2009) · Journal of Diabetes · doi:10.1111/j.1753-0407.2009.00043.x · Cited by 27
Self-citationLamp-2 deficiency prevents high-fat diet-induced obese diabetes via enhancing energy expenditure
Yasuda‒Yamahara, M., Kume, S., Yamahara, K., Nakazawa, J., Chin‒Kanasaki, M., Araki, H., Araki, S., Koya, D., Haneda, M., Ugi, S., et al. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.08.010 · Cited by 27
Alcarraz‐Vizán, G., Castaño, C., Visa, M., Montané, J., Servitja, J., & Novials, A. (2017) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-017-2505-1 · Cited by 27
Protein kinase STK25 aggravates the severity of non-alcoholic fatty pancreas disease in mice
Nuñez‐Durán, E., Chanclón, B., Sütt, S., Real, J. I., Marschall, H., Asterholm, I. W., Cansby, E., & Mahlapuu, M. (2017) · Journal of Endocrinology · doi:10.1530/joe-17-0018 · Cited by 29
Regulator of G protein signaling 2 is a key regulator of pancreatic β-cell mass and function
Dong, H., Zhang, Y., Wang, J., Kim, D. S., Wu, H., Sjögren, B., Gao, W., Luttrell, L. M., & Wang, H. (2017) · Cell Death and Disease · doi:10.1038/cddis.2016.216 · Cited by 26
Mongelli-Sabino, B. M., Canuto, L. P., & Collares‐Buzato, C. B. (2017) · Life Sciences · doi:10.1016/j.lfs.2017.09.004 · Cited by 27
Bergeron, V., Ghislain, J. J., Vivot, K., Tamarina, N. A., Philipson, L. H., Fielitz, J., & Poitout, V. (2017) · Diabetes · doi:10.2337/db17-0982 · Cited by 25
“G-protein–coupled receptors are validated targets for the treatment of T2D, and among these, the fatty acid receptor 1 (also known as GPR40/FFAR1) has been the subject of considerable interest in recent years (3).”
BackgroundInfluentialHuang, M. C., Douillet, C., & Stýblo, M. (2019) · Archives of Toxicology · doi:10.1007/s00204-019-02526-2 · Cited by 28
Reduced Cytochrome c Is an Essential Regulator of Sustained Insulin Secretion by Pancreatic Islets
Jung, S., Kuok, I. T., Couron, D., Rizzo, N. O., Margineantu, D. H., Hockenbery, D. M., Kim, F., & Sweet, I. R. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.202820 · Cited by 26
Meng, Z., Yin, Y., Lv, J., Sha, M., Lin, Y., Gao, L., Zhu, Y., Sun, Y., & Han, X. (2012) · Diabetologia · doi:10.1007/s00125-012-2516-2 · Cited by 26
Metadata
- Authors
- Prentki, M.
- Affiliations
- Centre Hospitalier de l’Université de Montréal (CA)
- Corresponding author
- Prentki, M.
- ORCID
- Prentki, M.
- Venue
- Journal of Clinical Investigation
- Published
- 2006-07-03
- Volume
- 116
- Issue
- 7
- Pages
- 1802-1812
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC1483155
- OpenAlex
- W1598254642
- Cited by
- 1,690
- References
- 132
- Citations by year
- 2026: 52 · 2025: 52 · 2024: 46 · 2023: 54 · 2022: 68 · 2021: 95 · 2020: 95 · 2019: 111 · 2018: 90 · 2017: 109 · 2016: 112 · 2015: 107 · 2014: 131 · 2013: 97 · 2012: 98
- FWCI
- 13.11
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- ANU Open Research (Australian National University) (submittedVersion)
- Funders
- ACT Government
- National Institutes of Health
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK063356, DK63356)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- beta-cell failure, type 2 diabetes, obesity, beta-cell compensation, beta-cell mass expansion, insulin resistance, genetic susceptibility, intrauterine factors, environmental risk factors, beta-cell dysfunction
- MeSH terms
- Animals, Diabetes Mellitus, Type 2, Humans, Insulin Resistance, Disease Progression, Genetic Predisposition to Disease, Insulin-Secreting Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.